DrugDev to Sponsor and Speak at Disruptive Innovation Conference on September 10-11 in Boston to Continue the Conversation of Clinical Trial Innovation
DrugDev’s President and CEO Ibs Mahmood to discuss strategies to reinvent the clinical trial; Advisory Board Chair Dr. Jeffrey Kasher to lead panel on the CRO of the future
King of Prussia, PA and London, UK – September 9, 2015 – DrugDev will promote the adoption of modern technology to lower the cost and upgrade the efficiency of clinical trials with its executive sponsorship and participation in the Disruptive Innovations US (DPharm) conference, September 10-11 in Boston.
DrugDev President and CEO Ibraheem (Ibs) Mahmood will discuss the critical need to standardize, collaborate and deliver a beautiful technology experience for all stakeholders including patients during the “Interview Segment with Change Agents for Industry” session led by Andreas Koester, MD, PhD, VP Innovation, R&D Operations, Janssen and Komathi Stem, MS, Strategic Innovation Leader, Genentech/Roche.
Also at DPharm, Dr. Jeffrey Kasher, Chair of the DrugDev Advisory Board and President of Patients Can’t Wait, will lead a panel discussion, “Disrupting the CRO: What Will Be the CRO of the Future?” Participants will include Andrew Lee, MD, SVP, Head of Global Clinical Trial Operations, Merck; Solomon Babani, MBA, Global VP, Alliance Management, Covance; Paul Colvin, RPH, EVP, Global Clinical Development, PPD; Jamie Macdonald, CEO, INC Research; and, Adrian McKemey, PhD, SVP and Managing Director, Advisory Services, Quintiles.